Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Tight junction protein ZO-1 and Occludin are key structural and regulatory components of tight junctions, which form selective barriers between adjacent epithelial or endothelial cells[1][2][5][6]. **ZO-1** is a scaffold protein encoded by the TJP1 gene; it is located on the cytoplasmic side of the cell membrane and organizes tight junctions by connecting transmembrane proteins (like occludin and claudins) to the actin cytoskeleton, thereby maintaining barrier selectivity and epithelial polarity[1][5][6][7]. Its multi-domain structure enables binding to numerous junctional proteins and cytoskeletal elements, playing roles in cytoskeletal organization, signal transduction, and mechanotransduction[2][5]. **Occludin** is a transmembrane protein spanning the membrane four times, with extracellular loops mediating intercellular adhesion and a C-terminal domain that interacts with ZO-1, essential for its trafficking and function at tight junctions[2][6]. Both proteins regulate the permeability of the paracellular pathway and participate in non-canonical functions such as apoptosis regulation, mechanosensing, and gene expression changes. Dysfunction or altered expression of ZO-1 and Occludin is implicated in a variety of diseases involving barrier breakdown, making them informative biomarkers and potential—but challenging—therapeutic targets[2][6][7].
Enhancement or restoration of tight junction integrity (indirect, via pathway modulation). Reduction of paracellular leak by stabilizing protein-protein or protein-cytoskeleton interactions. Inhibition of protein phosphorylation or disruption of scaffolding complex[4][7].
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Tight junction protein ZO-1 and Occludin (ZO-1 and Occludin).